Cargando…
Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience
Thrombosis risk in essential thrombocythemia (ET) patients can be assessed using different prognostic systems. Conventional risk factors include age more than 60 years and history of previous thrombosis. In addition, other factors such as JAK2 V617F mutations, cardiovascular risk factors, leukocytos...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709397/ https://www.ncbi.nlm.nih.gov/pubmed/26793025 http://dx.doi.org/10.5114/wo.2015.54083 |
_version_ | 1782409634023211008 |
---|---|
author | Dambrauskiene, Ruta Gerbutavicius, Rolandas Juozaityte, Elona Gerbutaviciene, Rima |
author_facet | Dambrauskiene, Ruta Gerbutavicius, Rolandas Juozaityte, Elona Gerbutaviciene, Rima |
author_sort | Dambrauskiene, Ruta |
collection | PubMed |
description | Thrombosis risk in essential thrombocythemia (ET) patients can be assessed using different prognostic systems. Conventional risk factors include age more than 60 years and history of previous thrombosis. In addition, other factors such as JAK2 V617F mutations, cardiovascular risk factors, leukocytosis more than 11 × 10(9)/l, thrombophilic factors and platelet count more than 1500 × 10(9)/l are used in different hematology centers as high-risk features for thrombosis. Our study compared different risk model groups for thrombosis in 185 WHO-defined ET patients at the Hospital of Lithuanian University of Health Sciences Kaunas Klinikos. We found that patient distribution in low, intermediate- and high-risk groups varies using different risk stratification models. The biggest difference in risk assignment is evident in patients who are older than 60 years and have no other risk factors and in patients who are younger than 60 years but have other risk factors. This observation suggests that new prospective randomized clinical trials are needed to better stratify patients at risk for thrombosis. |
format | Online Article Text |
id | pubmed-4709397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-47093972016-01-20 Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience Dambrauskiene, Ruta Gerbutavicius, Rolandas Juozaityte, Elona Gerbutaviciene, Rima Contemp Oncol (Pozn) Original Paper Thrombosis risk in essential thrombocythemia (ET) patients can be assessed using different prognostic systems. Conventional risk factors include age more than 60 years and history of previous thrombosis. In addition, other factors such as JAK2 V617F mutations, cardiovascular risk factors, leukocytosis more than 11 × 10(9)/l, thrombophilic factors and platelet count more than 1500 × 10(9)/l are used in different hematology centers as high-risk features for thrombosis. Our study compared different risk model groups for thrombosis in 185 WHO-defined ET patients at the Hospital of Lithuanian University of Health Sciences Kaunas Klinikos. We found that patient distribution in low, intermediate- and high-risk groups varies using different risk stratification models. The biggest difference in risk assignment is evident in patients who are older than 60 years and have no other risk factors and in patients who are younger than 60 years but have other risk factors. This observation suggests that new prospective randomized clinical trials are needed to better stratify patients at risk for thrombosis. Termedia Publishing House 2015-09-16 2015 /pmc/articles/PMC4709397/ /pubmed/26793025 http://dx.doi.org/10.5114/wo.2015.54083 Text en Copyright © 2015 Termedia http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Dambrauskiene, Ruta Gerbutavicius, Rolandas Juozaityte, Elona Gerbutaviciene, Rima Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience |
title | Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience |
title_full | Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience |
title_fullStr | Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience |
title_full_unstemmed | Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience |
title_short | Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience |
title_sort | thrombotic risk assessment in 185 who-defined essential thrombocythemia patients: single center experience |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709397/ https://www.ncbi.nlm.nih.gov/pubmed/26793025 http://dx.doi.org/10.5114/wo.2015.54083 |
work_keys_str_mv | AT dambrauskieneruta thromboticriskassessmentin185whodefinedessentialthrombocythemiapatientssinglecenterexperience AT gerbutaviciusrolandas thromboticriskassessmentin185whodefinedessentialthrombocythemiapatientssinglecenterexperience AT juozaityteelona thromboticriskassessmentin185whodefinedessentialthrombocythemiapatientssinglecenterexperience AT gerbutavicienerima thromboticriskassessmentin185whodefinedessentialthrombocythemiapatientssinglecenterexperience |